ArticleJournal of clinical medicine2023
Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP-STAR study.Journal of diabetes investigation · 2024Trial
- Temporal distribution of acute kidney injury-related hospitalizations after initiation of sodium-glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single-center eGFR analysis.Journal of diabetes investigation · 2026Article
- Association of prior Angiotensin receptor-neprilysin inhibitor use with the initial eGFR dip after initiation of SGLT2 inhibitors in patients with chronic kidney disease.Clinical and experimental nephrology · 2026Article
- Discontinuation of SGLT2i After a Urogenital Infection: A Population-Based Matched Cohort Study of Patients With Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Do the treatment selection factors emphasized in clinical guidelines-Chronic kidney disease, cardiovascular disease, and heart failure-contribute to the risk of urinary tract infections during the administration of sodium-glucose cotransporter-2 inhibitors?Journal of diabetes investigation · 2026Article
- Cost-Effectiveness Analysis of Artificial Intelligence-Driven Risk Stratification in Patients With Diabetic Kidney Disease in the US Veterans Population.Kidney medicine · 2026Article
- Sex-specific risk factors for genital infections associated with SGLT2 inhibitors in type 2 diabetes: a retrospective cohort study and disproportionality analysis using JADER.Therapeutic advances in drug safety · 2026Article
- Observational
- Clinical use and monitoring of adverse effects of sodium-glucose cotransporter-2 inhibitors in persons with type 1 diabetes mellitus.Journal of diabetes investigation · 2025Article
- Association of antidiabetic medications with psychiatric disorders in patients with type 2 diabetes: a cross-sectional study.European journal of medical research · 2025Article
- SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations.Medicina (Kaunas, Lithuania) · 2025Review
- Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes.Scientific reports · 2025Article
- Impact of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors on Nocturnal Polyuria: A Cross-Sectional Study.Cureus · 2025Article
- Differential Effects of SGLT-2 Inhibitors on Liver Function and Nocturia in Patients with Type 2 Diabetes: A Randomized Controlled Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Review
- Comparison over Time of Adverse Drug Reactions in Diabetes Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors.The Kobe journal of medical sciences · 2024Article
- Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium-Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the "Middle Child of HF"? Real-World Experience from a Single Clinical Centre.Journal of cardiovascular development and disease · 2024Article
- Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of antidiabetic agents known to exert cardioprotective, renoprotective, and hypoglycemic effects. However, these agents have been associated with adverse effects, such as genital infection, volume depletion, hypoglycemia, and diabetic ketoacidosis, resulting in drug discontinuation. Herein, we aimed to determine the reasons for discontinuing treatment with SGLT2is among Japanese patients with diabetes. This retrospective cohort study enrolled 766 patients with diabetes who had initiated SGLT2is between January 2014 and September 2021. The follow-up period was 2 years from the initiation of the SGLT2is. Overall, 97 patients (12.7%) discontinued the SGLT2is during the follow-up period. The most common reasons for discontinuing the SGLT2is were frequent urination (19.6%), followed by genital infection (11.3%), improved glycemic control (10.6%), and renal dysfunction (8.2%). A comparison of the characteristics between the continuation and the discontinuation group was conducted, excluding those who discontinued the SGLT2is because of improved glycemic control. The patients in the discontinuation group (68 [55-75] years) were older than those in the continuation group (64 [53-71] years;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.